Validation of In-vitro Deposition of Emitted Dose Method for Simultaneous Estimation of Formoterol Fumarate and Glycopyrrolate in combined Dry Powder Inhaler Aerosol Pharmaceutical Dosage Form
Abstract
Formoterol Fumarate and Glycopyrrolate Dry powder inhaler is combined aerosol dosage form. The label claim of this combined dosage form is 25 mcg of Glycopyrrolate and 6 mcg of Formoterol Fumarate per respicap. It is prescribed for treatment of Asthma and COPD. Formoterol Fumarate is anti asthmatic drug (Bronchodilator) and Glycopyrrolate is quaternary ammonium compounds which is Anticholinergic Drug. A bronchodilator is a substance that dilates the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs while Glycopyrrolate blocks muscarinic receptors thus inhibiting cholinergic transmission. Glycopyrrolate is also known as Glycopyrronium Bromide, an Anticholinergic agent. It is used to inhibit salivation and excessive secretions of the respiratory tract preoperatively; reversal of neuromuscular blockade; control of upper airway secretions; and part of treatment for peptic ulcer. The present study aimed to Validate HPLC method for determination of Deposition of emitted dose of Formoterol Fumarate and Glycopyrrolate Analytes. This study covers Precision, Linearity, Accuracy, Robustness, Ruggedness, stability of analytical solution and Specificity. The chromatographic method uses a reversed phase column Purosphere star RP 18e (125 mm × 4.6 mm x 5 μm). The mobile phase was prepared by mixing Buffer : Acetonitrile : Methanol (68 : 24 : 8 %v/v/v) at flow rate 1.0 ml per min with UV and PDA detector 215 nm, column oven adjusted to 25° C with injection volume 100 μL. The method showed a successful application for determination of Formoterol Fumarate and Glycopyrrolate in Dry powder inhaler pharmaceutical formulation.
Keywords:
Formoterol Fumarate, Glycopyrrolate, HPLC, Validation, Dry powder Inhaler, Respicaps.DOI
https://doi.org/10.25004/IJPSDR.2020.120511References
Ghany MF, Hussein LA, Magdy N, Yamani HZ. Simultaneous spectrophotometric determination of indacaterol and glycopyrronium in a newly approved pharmaceutical formulation using different signal processing techniques of ratio spectra. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2016 Mar 15;157:251-7.
Tamási L, Szilasi M, Gálffy G. Clinical effectiveness of budesonide/formoterol fumarate Easyhaler® for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. Advances in therapy. 2018 Aug 1;35(8):1140-52.
Lu Y, Sun Z, Zhang Y, Chen X, Zhong D. Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography–tandem mass spectrometry: application in a stereoselective pharmacokinetic study. Journal of Chromatography B. 2013 Mar 15;921:27-34.
Salem YA, Hammouda ME, El-Enin MA, El-Ashry SM. Multiple analytical methods for determination of formoterol and glycopyrronium simultaneously in their novel combined metered dose inhaler. BMC chemistry. 2019 Dec;13(1):75.
Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. John Wiley & Sons; 2011 Sep 20.
Ravi Sankar S. Text book of pharmaceutical analysis. 4th ed., Rx publication, Tirunelveli, 2005.
Sharma BK. Instrumental methods of chemical analysis. 23rd ed., Goel publishinghouse, meerut, 2004.
Guideline IH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005 Nov;1:1-5.
Elder D. ICH Q6A Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:433-66.
United States Pharmacopoeia 30 and National formulary 25. Rockville (MD): United State Pharmacopoeia Convention, 2007.
Pharmacopiea I. Government of India, Ministery of Health and Family welfare, New Delhi. The controller of publication. 1996
Kotak RK, Pandya CV, Pandya AC, Thakur B, Laddha R. Solubility study Of Formoterol Fumarate Dihydrate, Glycopyrrolate And Budesonide Drugs As A practical Tool For Analytical Method Development. International Journal of Technical Innovation in Modern Engineering & Science. 2019; 5-5:386-388
Salem YA, Shaldam MA, El-Sherbiny DT, El-Wasseef DR, El-Ashry SM. Simultaneous Determination of Formoterol Fumarate and Budesonide Epimers in Metered Dose Inhaler Using Ion-Pair Chromatography. Journal of chromatographic science. 2017 Nov 1;55(10):1013-20.
Pai N, Patil SS. Development and validation of RP-HPLC method for estimation of formoterol fumarate and budesonide in pressurised meter dose inhaler form. Der Pharmacia Sinica. 2013; 4: 15–26.
Farid NF, Abdelwahab NS. Development and Validation of Different Chromatographic Methods for Analysis of Cabergoline in the Presence of Its Degradation Products: Studying Degradation Profile. Chromatographia. 2019 Oct 1;82(10):1555-69.
Chatrabhuji P, Pandya C, Patel M. HPLC Method for Determination of APIs in pharmaceutical formulation. Lulu. com; 2015 Apr 17.
Patel VA, Pandya CV, Pandya AC, patel D, patel Z. Concurrent determination of Tenligliptin Hydrobromide Hydrate and Metformin Hydrochloride Development and Validation by UV-VIS Spectrophotometry in Bulk and Pharmaceutical Dosage form. International Journal of Technical Innovation in Modern Engineering & Science. 2019; 5-3: 296-303.
Kale NR, Pingle AP, Mirza JA, Dhongade GN. Development and validation of stability-indicating RP-HPLC method for simultaneous estimation of formoterol fumarate and budesonide in metered dose inhaler formulation. World Journal of Pharmaceutical Research. 2014 Jun 20;3(6):1386-99.
Published
Abstract Display: 445 
PDF Downloads: 569 
